“The key finding is the ability of the test to make an early prediction of response and disease control, just three to four weeks after initiation of immunotherapy. The flexibility to switch treatments early on based on an accurate prediction has great potential to improve the treatment of many cancers.”
“If you are able to tell after the first cycle that it isn’t working, it can bring significant savings to the healthcare payer.”
“Basic idea that we have is since each and every cell that you have in the body has its genomic material half from your father and half from your mother it shouldn’t change and it wont change all your life before you die but the cancer cells are actually really changing their geno so their genomic patterns are completely different from any other cell that you have in your body. That’s why we can specifically detect cancerous material in the plasma.“
Prof. Ekkehard Schütz, M.D., Ph.D., FACB, About CNI Tests
“A lot of chemotherapy is still being used in cancer patients; imagine being able to tell a patient after one cycle that the chemotherapy is not working, then they won’t have to go through five more cycles of toxic drugs that could be worse for them. So you can keep using our monitoring test to see how the patient is responding to the therapy until you hit on the right therapy that works.”
“It’s simple. If you have gains or losses in your blood, you have cancer somewhere,”
“Most of these tests that are currently being marketed are snip based single nucleotide polymorphisms where as chronix essay is based on chromosome instability and it looks at copy number aberrations and for this point of view it has the advantage that you can cover all types of cancer.”
Prof. Dr. med. Dr. h.c. Michael Oellerich, FACB, FAMM, FFPath (RCPI), FRCPath, Michael Oellerich, MD, Professor of George-August-University Göttingen.
“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard B. Urnovitz, Ph.D.
“We built our test so we could repeat the success the we saw on the HIV aid epidemic. In 1996 we introduced to the world a test the could look at how much virus was in the body a viral load test. From that medical researchers could then figure out what combinations of drugs to use so that no body dies unnecessary from aids anymore. We build our cancer load test to repeat that success, we expect that no one should die from cancer unnecessary.“
“The advantage of the method by Beck et al (Chronix Biomedical) is that it seems to allow the detection of cancer without needing access to tumour tissues. Other investigators, however, have taken a different route.”
“We Built the test to repeat history. The introduction of HIV viral load test in 1996 gave medical researchers a target to formulate treatment approaches to stop people from dying of Aids. We believe this CNI Cancer Monitor load test will Lead to a world where no one dies unnecessarily of cancer.”
“Liquid biopsies are going to be a major part of our anti-cancer armoury in the future. They will be used for diagnosis, prognosis and most importantly prediction, providing a real-time measure from a simple blood test of how a patient is responding”
Justin Stebbing, professor of cancer medicine and medical oncology at Imperial College London and Imperial College Healthcare NHS Trust., New blood test gives hope to cancer patients
“Doctors need every tool at their disposal to make medically important decisions. Today’s report illustrates the clinical utility of adding the Chronix Biomedical blood test to the current test menu to assist oncologists in important treatment decisions.“
“There is potential value in using liquid biopsies to monitor how a patient’s cancer might be changing. Liquid biopsies can be obtained more frequently and might help in the selection of the best possible treatments to combat the cancer. It could be an advantage in helping the patient if results of liquid biopsies give us the ability to know weeks in advance how a cancer is responding to treatment”
Dr Glen J. Weiss, director of clinical research at Cancer Treatment Centers of America at Western in Arizona., New blood test gives hope to cancer patients
“Most important applications would be for patients that are of high risk. That is to say they have a family history of cancer, are smokers, have genetic mutations associated with cancer. Those are first target groups. That eventually will then have a general sting for the general population.”
Howard B. Urnovitz, Ph.D.
“There are three potential scenarios when you get the result from Second Opinion. If the CNI score is low and, say, the mammogram is considered low-suspicion, that first scenario is for the doctor to look at the patient again in one year. The second scenario is if the CNI score is in the suspiciously high range, the doctor may say ‘we’ll look in 3-6 months’. If the CNI score is statistically above the threshold, you would send the patient to biopsy. Then if the biopsy confirms that it is cancer and the patient goes into treatment, that’s when you go into this response monitoring area with the CNI Cancer Monitor to see if the treatment works.”
“This study supports the potential of an entirely new approach to identifying cancer at its earliest stages when therapies may be most effective…. The promising diagnostic sensitivity and specificity achieved in this study further confirm the value of circulating DNA for disease detection and suggest that laboratory tests using this approach may have the potential both to screen large populations for cancer before symptoms appear and to monitor patients for the recurrence of cancer once treated.”
William M. Mitchell, M.D., Ph.D., Professor of Pathology at Vanderbilt University School of Medicine, Newly Published Data Shows Chronix Biomedical's Serum DNA Assays Can Detect Early-Stage Breast Cancer
“In the US, you’re looking at $120bn a year being spent on care of cancer patients. If you could screen people for the earliest stages of cancer and bend the arc towards more success stories you are bringing down tens of billions of dollars of cancer care that you don’t need to administer because you caught it early.”
“I think we are on the cutting edge of the biggest change that we ever seen in the history of medicine. Im talking about personalised or individualised medicine and now with revolution of genomics and genetics in the genome we are learning that each individual is very deferent from another therefore if we can find targets to direct a drug to that individuals need its going to change the whole face of medicine and to do that you’re going to need a diagnostic agent that provides that provides a deep dive into the genome to look at your gene structure so you can construct a medicine that works for the gene structure. Howard Urnovitz and Chronix are in the cutting edge of doing this today, they are in the lead and far ahead of everyone. “
Paul Freiman, Chairman, Chronix, about CNI Tests
“It’s the same CNI test each time, with Second Opinion and CNI Cancer Monitor. We’re just simply tracking fingerprints… The data are the data – if you have a spot on chromosome 1 and it’s a gain and you fail therapy, it’ll still be there. You’re always tracking the dynamics of the tumor change, that’s the beauty of doing the whole genome sequencing. You are not giving bias in the genes you want to select for, but you allow the patient to tell you what’s going on in their unique situation.”